Clinics in Developmental Medicine

The third edition of “The Gross Motor Function Measure (GMFM-66 & GMFM-88) User's Manual” has retained the information contained in the original 2002 and 2013 publications which included the conceptual background to the development of the GMFM, and the administration and scoring guidelines for people to be able to administer this clinical and research assessment tool appropriately. Information is presented on the development and validation of two abbreviated methods of estimating GMFM-66 scores using the GMFM-66-Item sets (GMFM-66-IS) and the GMFM-66-B&C (Basal & Ceiling), and updates are included on the Challenge module and the Quality FM, translations, and the use of the GMFM in populations other than cerebral palsy and Down syndrome.

This book covers both molecular and clinical aspects of Fragile X Syndrome (FXS) and premutation disorders so that new targeted treatments can be understood by clinicians and parents. It covers all premutation disorders including FXTAS, FXPOI and FXAND problems. The main focus is to help clinicians to give the best care possible to patients with FXS and to understand a multidisciplinary treatment approach. Underserved populations such as babies and toddlers with FXS and mothers with the full mutation are highlighted, including the treatments that can be beneficial to them. This book also discuss fragile X associated disorders as they impact the family whose proband has FXS. A highlight of this book is the international perspective on how different cultures deal with FXS and targeted treatments.

This comprehensive and authoritative book is structured in a logical way from pathology to clinical outcome. Throughout, information from the basic sciences is placed within the clinical context, and there is excellent use of illustrative figures and images. Written by leading obstetricians, neonatologists, paediatricians and pathologists, this volume collates the ever-increasing evidence, both pathological and epidemiological, for the critical role of the utero-placenta in neurodisability, both at term and preterm. It encapsulates new advances in antepartum and perinatal imaging, new clinical aspects of fetal compromise, recent evidence of endocrine, haematological and inflammatory origins of utero-placental dysfunction, and possible cerebro-protective interventions. This text is essential reading for everyone concerned with child development and the in utero origins of neurological disability.

This classic text on paediatric neurology is now in its fourth edition. Leading academics from around the world present evidence from their various areas of expertise, placing it firmly in the clinical context. Each chapter covers the basic science of the disorder and relevant genetic advances. New to this edition are chapters on fetal neurology, movement disorders, basal ganglia disease and psychogenic disorders. References at the end of each chapter are thorough, guiding the clinician to relevant further reading. The international team of editors has maintained the clinical approach of the late Jean Aicardi, which distinguishes this book from others in the field. Succinctly given, patient-focused information makes Aicardi's Diseases of Nervous System in Childhood a comprehensive yet readable resource for busy clinicians in paediatric neurology, general paediatrics, neurodisability and all the related medical disciplines.

This edition of the Gross Motor Function Measure (GMFM-66 & GMFM-88) User's Manual has retained the information contained in the original 2002 and 2013 publications, which included the conceptual background to the development of the GMFM, and the administration and scoring guidelines for people to be able to administer this clinical and research assessment tool appropriately. Information is presented on the development and validation of two abbreviated methods of estimating GMFM-66 scores using the GMFM-66-Item sets (GMFM-66-IS) and the GMFM-66-B&C (Basal & Ceiling), and updates are included on the Challenge module and the Quality FM, translations, and the use of the GMFM in populations other than cerebral palsy and Down syndrome.